Resistance to Prostaglandin E2 Promotes Monocyte Activation During Chronic HIV Infection

Area of Science:

• Immunology
• Virology
• Molecular Biology

Background:

• Monocyte activation drives inflammation in chronic HIV infection.
• Prostaglandin E2 (PGE2) typically inhibits pro-inflammatory cytokine production.
• Understanding PGE2's role in HIV-associated monocyte activation is crucial.

Purpose of the Study:

• To investigate PGE2's effects on monocyte activation in chronic HIV.
• To elucidate mechanisms by which PGE2 modulates monocyte inflammatory signatures.
• To compare PGE2 levels, monocyte activation, and PGE2 sensitivity in people with HIV (PWH) and controls.

Main Methods:

• Recruited people with HIV (PWH) and healthy controls.
• Measured plasma PGE2 levels.
• Assessed monocyte activation and sensitivity to PGE2's inhibitory actions.

Main Results:

• PWH showed increased plasma PGE2 and activated monocytes.
• Monocytes from PWH were resistant to PGE2's inhibitory effects (10x higher PGE2 needed to inhibit TNF-α).
• Increased phosphodiesterase 4B expression was observed in PWH monocytes.

Conclusions:

• Monocyte resistance to PGE2 contributes to inflammation in PWH.
• This resistance may be linked to increased phosphodiesterase 4B.
• Findings offer insights into HIV-associated inflammatory processes.